Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer
- PMID: 35654050
- DOI: 10.1016/S1470-2045(22)00261-3
Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer
Conflict of interest statement
GR reports participating in lectures and educational activities and consulting or advisory roles for Amgen, Bayer, Biocartis, Bristol-Myers Squibb, Merck Serono, Merck, Sharp & Dohme, Pfizer, Roche, Takeda; research grants from Amgen and Janssen; and travel expenses from Roche. LM reports participating in lectures and educational activities for Bristol-Myers Squibb, AstraZeneca, Roche, Takeda; consulting or advisory roles for Roche and Takeda; research grants from Bristol-Myers Squibb, Boehringer Ingelheim, Amgen, Stilla, and Inivata; travel, accommodations, and expenses from Bristol-Myers Squibb, Roche, Takeda, and AstraZeneca; and support from the Contrato Juan Rodes 2020 (Instituto de Salud Carlos III, Ministry of Health, Spain) and Ayuda SEOM-Juan Rodés 2020.
Comment on
-
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576957 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials